-transparent.png){kind=logo}
Bleomycin is an agent with significant antitumor efficacy whose major dose limiting toxicity is pulmonary fibrosis. Attempts have thus been made to identify congeners with reduced toxicity and with comparable or greater antitumor activity. Tallysomycin S10b is a bleomycin analogue possessing significantly greater potency, equal or reduced lung toxicity, and slightly greater antineoplastic activity when compared to the parent compound in preclinical studies. This report describes our experience with tallysomycin S10b in 30 patients with a variety of non-hematologic neoplasms. Pulmonary toxicity, occurring in 4 patients, was the major toxicity. The recommended cumulative dose of tallysomycin S10b was difficult to establish from the results of this study, as pulmonary toxicity appeared to be more idiosyncratic than dose- or schedule-dependent. The employment of more sensitive methods for detecting pulmonary toxicity in this study suggest that tallysomycin S10b may have reduced pulmonary toxicity compared to the parent compound. Both bleomycin and tallysomycin S10b have similar t1/2 beta half-lives of 2-4 h. Six patients had prolonged terminal elimination half-lives of tallysomycin S10b, but no clear relationship between this phenomenon and efficacy or toxicity was evident. No complete or partial responses occurred. Disease stabilization occurred in 4 of 15 patients with diagnoses of renal cell carcinoma, rectal cancer and lung cancer. Five of eight patients with non-measurable disease had stable disease, including one with mesothelioma, one with carcinoma of the head and neck, two with renal cell cancer and one with colon carcinoma.
F P Paolozzi, and
R C Gaver, and
N B Newman, and
B J Poiesz, and
S DeFino, and
A Louie, and
R L Comis
January 1989,
Cancer chemotherapy and pharmacology,
F P Paolozzi, and
R C Gaver, and
N B Newman, and
B J Poiesz, and
S DeFino, and
A Louie, and
R L Comis
June 1981,
The Journal of antibiotics,
F P Paolozzi, and
R C Gaver, and
N B Newman, and
B J Poiesz, and
S DeFino, and
A Louie, and
R L Comis
January 1984,
Drug and chemical toxicology,
F P Paolozzi, and
R C Gaver, and
N B Newman, and
B J Poiesz, and
S DeFino, and
A Louie, and
R L Comis
March 1989,
Cancer research,
F P Paolozzi, and
R C Gaver, and
N B Newman, and
B J Poiesz, and
S DeFino, and
A Louie, and
R L Comis
January 1984,
Cancer chemotherapy and pharmacology,
F P Paolozzi, and
R C Gaver, and
N B Newman, and
B J Poiesz, and
S DeFino, and
A Louie, and
R L Comis
January 1990,
Cancer chemotherapy and pharmacology,
F P Paolozzi, and
R C Gaver, and
N B Newman, and
B J Poiesz, and
S DeFino, and
A Louie, and
R L Comis
August 1990,
Investigational new drugs,
F P Paolozzi, and
R C Gaver, and
N B Newman, and
B J Poiesz, and
S DeFino, and
A Louie, and
R L Comis
December 1978,
Biochemical and biophysical research communications,
F P Paolozzi, and
R C Gaver, and
N B Newman, and
B J Poiesz, and
S DeFino, and
A Louie, and
R L Comis
January 1986,
Cancer chemotherapy and pharmacology,
F P Paolozzi, and
R C Gaver, and
N B Newman, and
B J Poiesz, and
S DeFino, and
A Louie, and
R L Comis
January 1981,
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
